Ключові слова
Ревматоїдний артрит, антитіла до циклічного цитрулінованого пептиду, ревматоїдний фактор, клінічна значущість, прогностична значущість.
Як цитувати
Iaremenko, O., & Mykytenko, G. (2014). Порівняльна оцінка клінічної та прогностичної значущості антитіл до циклічного цитрулінованого пептиду та ревматоїдного фактору при ревматоїдному артриті. Практикуючий лікар, (3), 73-77. вилучено із https://plr.com.ua/index.php/journal/article/view/335
Анотація
На підставі даних первинного обстеження та 2-річного спостереження за 147 хворими на ревматоїдний артрит (РА) встановлено, що частота виявлення як антитіл до циклічного цитрулінованого пептиду (анти-ЦЦП), так і ревматоїдного фактору (РФ) лінійно зростає залежно від тривалості хвороби. Наявність у крові хворих анти-ЦЦП асоціюється з вищою порівняно з РФ активністю РА, більшою частотою появи позасуглобових проявів і гіршою клінічною та рентгенологічною відповіддю на лікування.
Посилання
1. Anticitrullinated protein antibodies and rheumatoid factor fluctuate in early inflammatory arthritis and do not predict clinical outcomes / L. Barra, V. Bykerk,
J.E. Pope [et al.] // J.Rheumatol. – 2013. – Vol. 40. – P. 1259-1267.
2. Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project) / A. Kastbom, G. Strandberg, A. Lindroos,
T. Skogh // Ann. Rheum. Dis. – 2004. – Vol. 63. – P. 1085-1089.
3. Avouac J. Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review / J. Avouac, L. Gossec,
M. Dougados // Ann. Rheum. Dis. – 2006. – Vol. 65. – P. 845-851.
4. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies / G.A. Schellekens, B.A.de Jong, F.H. van
der Hoogen [et al.] // J. Clin. Invest. – 1998. – Vol. 101. – P. 273-281.
5. Jansen A.L. Rheumatoid factor and antibodies to cyclic citrullinated peptide differentiate rheumatoid arthritis from undifferentiated polyarthritis in patients
with early arthritis / A.L. Jansen, I. van der Horst-Bruinsma, D. van Schaardenburg // J. Rheumatol. – 2002. – Vol. 29. – P. 2074-2076.
6. Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: anti-CP status predicts worse
disease activity and greater radiological progression / J. Rönnelid, M.C. Wick, J. Lampa [et al.] //Ann. Rheum. Dis. – 2005. – Vol. 64. – P. 1744-1749.
7. Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP) / K. Forslind, M. Almen,
K. Eberhardt [et al.] // Ann. Rheum. Dis. – 2004. – Vol. 63. – P. 1090-1095.
8. Presence and utility of IgA–class antibodies to cyclic citrullinated peptides in early rheumatoid arthritis: the Swedish TIRA project / A. Svard, A. Kastbom, A. Reckner-
Olsson, T. Skogh // Arthr. Res. Ther.- 2008. – Vol. 10. – R75.
9. Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgARF
at disease onset / E. Berglin, T. Johansson, U. Sundin [et al.] // Ann. Rheum. Dis. – 2006. – Vol. 65. – P. 453-458.
10. Repeated anticitrullinated protein antibody and rheumatoid factor assessment is not necessary in early arthritis: results from the ESPOIR Cohort / L. Gossec, S. Paternotte,
B. Combe [et al.] // J. Rheum. – 2014. – Vol. 41. – P. 41-46.
11. Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative / D. Aletaha,
T. Neogi, A.J. Silman [et al.] // Ann. Rheum. Dis. – 2010. – Vol. 69. – Р. 1580-1588.
12. Rheumatoid factor and antibodies to cyclic citrullinated peptides are associated with severe extra-articular manifestation in rheumatoid arthritis / C. Turesson,
L.T.H. Jacobsson, G. Sturfelt [et al.] // Ann. Rheum. Dis. – 2007. – Vol.66. – P. 59-64.
13. Rheumatoid factor and anticitrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extraarticular
manifestations / L. De Rycke, I. Peene, I.E. Hoffman [et al.] // Ann. Rheum. Dis. – 2004. – Vol.63. – P. 1587-1593.
14. Syversen S.W. High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid
arthritis: results from a 10-year longitudinal study / S.W. Syversen, P.I. Gaarder, G.L. Goll // Ann. Rheum. Dis. – 2008. – Vol. 67. – P. 212-217.
15. The major synovial targets of rheumatoid arthritis-specific antifillaggrin autoantibodies are deiminated forms of the alpha- and beta-chains of fibrin / C. Masson-
Bessierre, M. Sebbag, E. Girbal-Neuhauser [et al.] // J. Immunol. – 2003. – Vol. 166. – P. 4177-4184.
16. The presence of anti-cyclic citrullinated peptide antibody is associated with magnetic resonance imaging detection of bone marrow oedema in early stage
rheumatoid arthritis / M. Tamai, A. Kawakami, M. Uetani [et al.] // Ann. Rheum. Dis. – 2006. – Vol. 65. – P. 133-134.
17. van Venrooij W.J. Anticitrullinated protein/peptide antibody and its role in the diagnosis and prognosis of early rheumatoid arthritis / W.J. van Venrooij, J.M. Hazes,
H. Visser // Neth. J. Med. – 2002. – Vol. 60. – P. 383-388.
J.E. Pope [et al.] // J.Rheumatol. – 2013. – Vol. 40. – P. 1259-1267.
2. Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project) / A. Kastbom, G. Strandberg, A. Lindroos,
T. Skogh // Ann. Rheum. Dis. – 2004. – Vol. 63. – P. 1085-1089.
3. Avouac J. Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review / J. Avouac, L. Gossec,
M. Dougados // Ann. Rheum. Dis. – 2006. – Vol. 65. – P. 845-851.
4. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies / G.A. Schellekens, B.A.de Jong, F.H. van
der Hoogen [et al.] // J. Clin. Invest. – 1998. – Vol. 101. – P. 273-281.
5. Jansen A.L. Rheumatoid factor and antibodies to cyclic citrullinated peptide differentiate rheumatoid arthritis from undifferentiated polyarthritis in patients
with early arthritis / A.L. Jansen, I. van der Horst-Bruinsma, D. van Schaardenburg // J. Rheumatol. – 2002. – Vol. 29. – P. 2074-2076.
6. Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: anti-CP status predicts worse
disease activity and greater radiological progression / J. Rönnelid, M.C. Wick, J. Lampa [et al.] //Ann. Rheum. Dis. – 2005. – Vol. 64. – P. 1744-1749.
7. Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP) / K. Forslind, M. Almen,
K. Eberhardt [et al.] // Ann. Rheum. Dis. – 2004. – Vol. 63. – P. 1090-1095.
8. Presence and utility of IgA–class antibodies to cyclic citrullinated peptides in early rheumatoid arthritis: the Swedish TIRA project / A. Svard, A. Kastbom, A. Reckner-
Olsson, T. Skogh // Arthr. Res. Ther.- 2008. – Vol. 10. – R75.
9. Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgARF
at disease onset / E. Berglin, T. Johansson, U. Sundin [et al.] // Ann. Rheum. Dis. – 2006. – Vol. 65. – P. 453-458.
10. Repeated anticitrullinated protein antibody and rheumatoid factor assessment is not necessary in early arthritis: results from the ESPOIR Cohort / L. Gossec, S. Paternotte,
B. Combe [et al.] // J. Rheum. – 2014. – Vol. 41. – P. 41-46.
11. Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative / D. Aletaha,
T. Neogi, A.J. Silman [et al.] // Ann. Rheum. Dis. – 2010. – Vol. 69. – Р. 1580-1588.
12. Rheumatoid factor and antibodies to cyclic citrullinated peptides are associated with severe extra-articular manifestation in rheumatoid arthritis / C. Turesson,
L.T.H. Jacobsson, G. Sturfelt [et al.] // Ann. Rheum. Dis. – 2007. – Vol.66. – P. 59-64.
13. Rheumatoid factor and anticitrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extraarticular
manifestations / L. De Rycke, I. Peene, I.E. Hoffman [et al.] // Ann. Rheum. Dis. – 2004. – Vol.63. – P. 1587-1593.
14. Syversen S.W. High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid
arthritis: results from a 10-year longitudinal study / S.W. Syversen, P.I. Gaarder, G.L. Goll // Ann. Rheum. Dis. – 2008. – Vol. 67. – P. 212-217.
15. The major synovial targets of rheumatoid arthritis-specific antifillaggrin autoantibodies are deiminated forms of the alpha- and beta-chains of fibrin / C. Masson-
Bessierre, M. Sebbag, E. Girbal-Neuhauser [et al.] // J. Immunol. – 2003. – Vol. 166. – P. 4177-4184.
16. The presence of anti-cyclic citrullinated peptide antibody is associated with magnetic resonance imaging detection of bone marrow oedema in early stage
rheumatoid arthritis / M. Tamai, A. Kawakami, M. Uetani [et al.] // Ann. Rheum. Dis. – 2006. – Vol. 65. – P. 133-134.
17. van Venrooij W.J. Anticitrullinated protein/peptide antibody and its role in the diagnosis and prognosis of early rheumatoid arthritis / W.J. van Venrooij, J.M. Hazes,
H. Visser // Neth. J. Med. – 2002. – Vol. 60. – P. 383-388.
Завантаження
Дані завантаження ще не доступні.